Shots:
- Klinge Pharma, holder of global commercialization rights for Formycon’s FYB203, has entered into an exclusive agreement with NTC to commercialize FYB203, a biosimilar version of Eylea (aflibercept), in Italy
- As per the deal, Klinge will receive royalties on net sales, with Formycon participating in these payments in the mid-single to low-double-digit % range, while also serving as the authorized designee to manage FYB203 supply chain & earning additional service payments plus a volume-based profit component for organizing the commercial supply on behalf of Klinge
- FYB203 received the US FDA approval in Jun 2024 & EC approval under brand names Ahzantive & Baiama in Jan 2025, followed by MHRA approval in Feb 2025
Ref: Formycon | Image: Klinge Pharma and NTC | Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
